share_log

Ocugen | 8-K: Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Ocugen | 8-K: Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Ocugen | 8-K：Ocugen提供2024年第二季度財務業績的最新業務情況
美股SEC公告 ·  2024/08/08 13:09

Moomoo AI 已提取核心訊息

Ocugen reported Q2 2024 financial results, highlighting progress in its gene therapy programs. The company is actively dosing patients in OCU400 Phase 3 trial for retinitis pigmentosa and has completed dosing in the third cohort of OCU410 Phase 1/2 trial for geographic atrophy. The FDA approved an expanded access program for OCU400, marking it as the first gene therapy candidate for RP to receive such approval.Financial results showed operating expenses of $16.6M for Q2 2024, down from $24.0M in Q2 2023. The company reported a net loss of $0.04 per share, compared to $0.10 in the prior year. Cash position stood at $16.0M as of June 30, 2024. Subsequently, Ocugen raised $32.6M through a public offering, extending its cash runway into Q3 2025.The company continues to advance its pipeline, with OCU410 preliminary data expected later this year. The Phase 3 liMeliGhT trial for OCU400 includes 150 participants and is powered at over 95% assuming a 50% responder rate. Ocugen is actively pursuing strategic partnerships to support its novel modifier gene therapies globally.
Ocugen reported Q2 2024 financial results, highlighting progress in its gene therapy programs. The company is actively dosing patients in OCU400 Phase 3 trial for retinitis pigmentosa and has completed dosing in the third cohort of OCU410 Phase 1/2 trial for geographic atrophy. The FDA approved an expanded access program for OCU400, marking it as the first gene therapy candidate for RP to receive such approval.Financial results showed operating expenses of $16.6M for Q2 2024, down from $24.0M in Q2 2023. The company reported a net loss of $0.04 per share, compared to $0.10 in the prior year. Cash position stood at $16.0M as of June 30, 2024. Subsequently, Ocugen raised $32.6M through a public offering, extending its cash runway into Q3 2025.The company continues to advance its pipeline, with OCU410 preliminary data expected later this year. The Phase 3 liMeliGhT trial for OCU400 includes 150 participants and is powered at over 95% assuming a 50% responder rate. Ocugen is actively pursuing strategic partnerships to support its novel modifier gene therapies globally.
Ocugen報告了2024年第二季度財務業績，強調了其基因治療項目的進展。該公司正在積極對參與OCU400 III期試驗的視網膜色素變性患者進行給藥，並已完成OCU410 I/II期試驗第三組的給藥。FDA批准了OCU400的擴展訪問計劃，標誌着其成爲首個獲得此類批准的視網膜色素變性基因治療候選藥物。財務數據顯示2024年第二季度營業費用爲1660萬美元，低於2023年第二季度的2400萬美元。該公司報告每股淨虧損爲0.04美元，相較於之前的0.10美元。截止2024年6月30日，現金餘額爲1600萬美元。隨後，Ocugen通過公開發行籌集了3260萬美元，延長了其現金支出至2025年第三季度。該公司繼續推進其管道，預計將於今年晚些時候公佈OCU410的初步數據。OCU400的III期liMeliGht試驗包括150名參與者，其主要指標的有效性超過95%，假設應答率爲50%。Ocugen正在積極尋求戰略合作伙伴，以支持其全球新型修飾基因療法。
Ocugen報告了2024年第二季度財務業績，強調了其基因治療項目的進展。該公司正在積極對參與OCU400 III期試驗的視網膜色素變性患者進行給藥，並已完成OCU410 I/II期試驗第三組的給藥。FDA批准了OCU400的擴展訪問計劃，標誌着其成爲首個獲得此類批准的視網膜色素變性基因治療候選藥物。財務數據顯示2024年第二季度營業費用爲1660萬美元，低於2023年第二季度的2400萬美元。該公司報告每股淨虧損爲0.04美元，相較於之前的0.10美元。截止2024年6月30日，現金餘額爲1600萬美元。隨後，Ocugen通過公開發行籌集了3260萬美元，延長了其現金支出至2025年第三季度。該公司繼續推進其管道，預計將於今年晚些時候公佈OCU410的初步數據。OCU400的III期liMeliGht試驗包括150名參與者，其主要指標的有效性超過95%，假設應答率爲50%。Ocugen正在積極尋求戰略合作伙伴，以支持其全球新型修飾基因療法。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Corcept醫療
    CORT
    -- 114.220
    ABVC BioPharma
    ABVC
    -- 1.0600
    bluebird bio
    BLUE
    -- 4.880
    NLS Pharmaceutics
    NLSP
    -- 1.5400
    DBV Technologies
    DBVT
    -- 6.820
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點